Immunohistochemical characterization of CD33 expression on microglia in Nasu-Hakola disease brains

Neuropathology

Volumn 35, Issue 6, 2015, Pages 529-537

  Satoh, Jun ichi ^a   Kino, Yoshihiro ^a   Motohashi, Nobutaka ^b   Ishida, Tsuyoshi ^c   Yagishita, Saburo ^d   Jinnai, Kenji ^e   Arai, Nobutaka ^f   Nakamagoe, Kiyotaka ^g   Tamaoka, Akira ^g   Saito, Yuko ^h   Arima, Kunimasa ⁱ  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c National Center for Global Health and Medicine   (Japan)

^d KANAGAWA REHABILITATION CENTER   (Japan)

^e National Hospital Organization Hyogo Chuo National Hospital   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

ⁱ Komoro Kogen Hospital   (Japan)

Author keywords

CD33; DAP12; Microglia; Nasu Hakola disease; TREM2

Indexed keywords

CD33 ANTIGEN; GAMMA INTERFERON; IBA1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PROTEIN; UNCLASSIFIED DRUG; CD33 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; BONE CYST; BRAIN; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GLIOBLASTOMA; HEK293 CELL LINE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOENCEPHALOPATHY; MACROPHAGE; MALE; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; MYOTONIC DYSTROPHY; NASU HAKOLA DISEASE; NERVE CELL; NEUROBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WHITE MATTER; WHITE MATTER LESION; BIOSYNTHESIS; CHONDRODYSPLASIA; LIPODYSTROPHY; METABOLISM; PATHOLOGY; SUBACUTE SCLEROSING PANENCEPHALITIS;

BLOTTING, WESTERN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPODYSTROPHY; MALE; MICROGLIA; MIDDLE AGED; OSTEOCHONDRODYSPLASIAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALIC ACID BINDING IG-LIKE LECTIN 3; SUBACUTE SCLEROSING PANENCEPHALITIS;

EID: 84949323946     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12222     Document Type: Article

References (38)

1. Nasu T, Tsukahara Y, Terayama K. A lipid metabolic disease - "Membranous lipodystrophy" - an autopsy case demonstrating numerous peculiar membrane-structures composed of compound lipid in bone and bone marrow and various adipose tissues. Acta Pathol Jpn 1973; 23: 539-558.
2. Hakola HP. Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl 1972; 232: 1-173.
3. Bianchin MM, Capella HM, Chaves DL et al. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy - PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol 2004; 24: 1-24.
4. Tanaka J. Nasu-Hakola disease: a review of its leukoencephalopathic and membranolipodystrophic features. Neuropathology 2000; 20: S25-S29.
5. Kaneko M, Sano K, Nakayama J, Amano N. Nasu-Hakola disease: The first case reported by Nasu and review. Neuropathology 2010; 30: 463-470.
6. Aoki N, Tsuchiya K, Togo T et al. Gray matter lesions in Nasu-Hakola disease: a report on three autopsy cases. Neuropathology 2011; 31: 135-143.
7. Paloneva J, Manninen T, Christman G et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 2002; 71: 656-662.
8. Wang Y, Cella M, Mallinson K et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015; 160: 1-11.
9. Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 2009; 10: 340-347.
10. Satoh J. Possible role of microgliopathy in the pathogenesis of Nasu-Hakola disease. Clin Exp Neuroimmunol 2013; 4(Suppl 1): 17-26.
11. Kaifu T, Nakahara J, Inui M et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003; 111: 323-332.
12. Roumier A, Béchade C, Poncer JC et al. Impaired synaptic function in the microglial KARAP/DAP12-deficient mouse. J Neurosci 2004; 24: 11421-11428.
13. Nataf S, Anginot A, Vuaillat C et al. Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol 2005; 166: 275-286.
14. Otero K, Turnbull IR, Poliani PL et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol 2009; 10: 734-743.
15. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005; 201: 647-657.
16. Satoh J, Tabunoki H, Ishida T et al. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology 2011; 31: 363-375.
17. Crocker PR, McMillan SJ, Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. Ann NY Acad Sci 2012; 1253: 102-111.
18. Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 2005; 35: 243-251.
19. Griciuc A, Serrano-Pozo A, Parrado AR et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78: 631-643.
20. Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 2010; 132: 18-26.
21. Wang Y, Neumann H. Alleviation of neurotoxicity by microglial human Siglec-11. J Neurosci 2010; 30: 3482-3488.
22. Linnartz B, Neumann H. Microglial activatory (immunoreceptor tyrosine-based activation motif)- and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx. Glia 2013; 61: 37-46.
23. Satoh J, Motohashi N, Kino Y et al. LC3, an autophagosome marker, is expressed on oligodendrocytes in Nasu-Hakola disease brains. Orphanet J Rare Dis 2014; 9: 68.
24. Yagishita S, Ito Y, Sakai H, Amano N. Membranocystic lesions of the lung in Nasu-Hakola disease. Virchows Arch A Pathol Anat Histopathol 1985; 408: 211-217.
25. Motohashi N, Shinohara M, Shioe K, Fukuzawa H, Akiyama Y, Kariya T. A case of membranous lipodystrophy (Nasu-Hakola disease) with unique MRI findings. Neuroradiology 1995; 37: 549-550.
26. Nakamagoe K, Shioya A, Yamaguchi T et al. A Japanese case with Nasu-Hakola disease of DAP12 gene mutation exhibiting precuneus hypoperfusion. Intern Med 2011; 50: 2839-2844.
27. Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 2006; 79: 46-58.
28. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011; 11: 775-787.
29. Orr SJ, Morgan NM, Elliott J et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 2007; 109: 1061-1068.
30. Hollingworth P, Harold D, Sims R et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435.
31. Naj AC, Jun G, Beecham GW et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-441.
32. Bradshaw EM, Chibnik LB, Keenan BT et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013; 16: 848-850.
33. Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, Lue LF. Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging 2015; 36: 571-582.
34. Jonsson T, Stefansson H, Steinberg S et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-116.
35. Guerreiro R, Wojtas A, Bras J et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-127.
36. Wang Y, Cella M, Mallinson K et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015; 160: 1061-1071.
37. Guerreiro RJ, Lohmann E, Brás JM et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol 2013; 70: 78-84.
38. Zhang B, Gaiteri C, Bodea LG et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013; 153: 707-720.